

22 February 2023

Dear HCP,

This notice is to inform you of a change in how ancillary supplies will be provided for patients on Alprolix® or Eloctate®.

In place of providing ancillaries attached to the box containing drug product, ancillary supplies will be available to patients, free of charge, by requesting they be shipped directly to their residence or to their treatment centre of choice. A 3-month supply of the following ancillaries will be shipped to each patient at regular intervals as required:

- Butterfly needle
- Bandages
- Alcohol pads
- Gauze pads

Product without the ancillaries attached will be gradually introduced into Canada starting **May 2023.**

The reason for this change is to help improve the ability to provide a consistent supply of drug product, without the constraints of attaching ancillary supplies that may slow down or complicate supply chain management. It also allows HCPs and patients to individualize ancillary supplies as required without wastage.

Effective **April 1, 2023**, there will be 2 options available to obtain necessary supplies for infusion of Alprolix® or Eloctate®:

- Enrol the patient into the Rare Together PSP (see attached enrolment form). Patients will
 have access to infusion training and support services, including shipment of necessary
 ancillaries directly to their home, and additional items such as pooling syringes and sharps
 containers.
- 2. HCPs can request ancillary supplies be shipped for patients who have been prescribed Alprolix® or Eloctate® either to their home, or to their closest treatment centre for pickup. You can arrange shipments using the following email: HemoSupplies@Bayshore.ca (email will be active, effective March 1st).

IMPORTANT: Supplies will need to be arranged by **May 1**st to ensure all patients have the ancillaries they need.

We appreciate your trust in Alprolix® and Eloctate® for meeting your patient's needs. Please contact us at the number below if you have any questions or concerns.

Sincerely,

Greg Stephenson

Marketing Lead, Rare Blood Disorders

Sanofi

Greg.stephenson@sanofi.com

Greg Stephenson

416-268-0215